Displaying drugs 6901 - 6925 of 8028 in total
Fasitibant
Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee).
Investigational
Matched Description: … trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of …
LY-3200882
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
Investigational
Matched Description: … LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab …
Eluforsen
Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients).
Investigational
Matched Description: … Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous …
Nedisertib
Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).
Investigational
Matched Description: … Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine …
Surzebiclimab
Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).
Investigational
Matched Description: … Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination …
Torudokimab
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Matched Description: … Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With …
SerpinPC
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of …
Rusfertide
Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of polycythemia vera and beta-thalassemia.
Investigational
Matched Description: … Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of …
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Matched Description: … SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis …
PNT001
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
RC118
RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.
Investigational
Matched Description: … RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal …
DDP-225
DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a...
Investigational
Matched Description: … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the ... The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered …
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … these have met the requirements of an ideal oral drug candidate. ... excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of …
Loprazolam
Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence...
Experimental
Matched Description: … It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. ... It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Matched Description: … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial ... In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Description: … novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional …
Amperozide
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia …
Pyrroloquinoline Quinone
A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]
Experimental
Matched Description: … It is a coenzyme of some DEHYDROGENASES. [PubChem] …
Adenosine 5'-phosphosulfate
5'-Adenylic acid, monoanhydride with sulfuric acid. The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.
Experimental
Investigational
Matched Description: … The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. …
Displaying drugs 6901 - 6925 of 8028 in total